Be the first to know

Never miss an update from CSL. Did you know that during reporting season, the announcements from ASX:CSL often move the market?

CSL (ASX:CSL) Company Logo

By joining StockLight, you agree to our Terms & Conditions and Privacy Policy
Create Alert Follow CSL

CSL (CSL)

AU ASX:CSL (135.2B)

296.34
-0.77 (-0.26%)
0:10am AEDT
LOADING
Loading price chart..

Summary

Current Price: $296.34
52w High/Low: $242.67 - 342.75
Market Cap: 135.2B
Price/Earnings: 44.01
Dividend Yield: 0.99%
Volume/Average: 726K - $933
CSL (ASX:CSL) Company Logo

Listed in 1994

Development, manufacturing and marketing of pharmaceutical and diagnostic products, cell culture media and human plasma fractions.
CSL (ASX:CSL) Company Logo

Development, manufacturing and marketing of pharmaceutical and diagnostic products, cell culture media and human plasma fractions.

Annual Reports

Annual Report to shareholders Sep 3rd 2020
2020
(5.8mb)
CSL Annual Report 2018/19 Sep 5th 2019
2019
(6.8mb)
CSL Annual Report to shareholders Sep 13th 2018
2018
(5.8mb)
Annual Report to Shareholders Sep 14th 2017
2017
(5.8mb)
Annual Report to shareholders Sep 8th 2016
2016
(5.5mb)
Annual Report to shareholders Sep 11th 2015
2015
(4.3mb)

Dividend History

Quantitative Ratios

Stock Ratios Locked
You viewed 3 companies today
Ratios will be unlocked
again tomorrow or;

Unlock these ratios,
configure alerts
and much more...

Download StockLight

All Ratios, Alerts and other features are available in our iOS and Android apps:
Download on iOS Download on Android

We are working on updating this web app to fully enable Quantitative Ratios. All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app.
Dividend Yield
1.6%
 
1.0%
 
 
Industry Avg
CSL

UNATTRACTIVE: CSL's dividend yield of 1.0% is less than the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more
Implied Growth
26.0%
 
7.7%
 
 
Industry Avg
CSL

ATTRACTIVE: CSL exhibits an implied growth ratio which is less than the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. CSL calculation: 10% - ($6.72 / $296.34) = 7.7% more
Price / Book
6.4
 
14.4
 
 
Industry Avg
CSL

UNATTRACTIVE: CSL exhibits a price/book ratio which exceeds the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more
Price / Earnings
29.9
 
44.8
 
 
Industry Avg
CSL

UNATTRACTIVE: CSL's price/earnings ratio of 44.8 exceeds the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more
Price / Sales
23.6
 
10.3
 
 
Industry Avg
CSL

ATTRACTIVE: CSL exhibits a price/sales ratio which is less than the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more

Company News

2 of the best ASX 50 shares you could buy right now
October 22nd, 2020 - Motley Fool

CSL Limited (ASX: CSL) The first ASX 50 share I would buy is CSL. I think the biotherapeutics giant is a great long term investment option due to the quality of its CSL Behring and Seqirus businesses. CSL Behring is the biotech business behind imm...

S&P places Cimic Group (ASX:CIM) on negative credit watch
October 22nd, 2020 - Motley Fool

Rationale of the Cimic Group decision Thiess delivers open cut and underground mining services in Australia, Asia and Africa. The company delivered an earnings before interest, taxes, depreciation and amortisation (EBITDA) margin of 34%. This is i...

The ASX healthcare shares I would buy and hold until at least 2030
October 21st, 2020 - Motley Fool

iShares Global Healthcare ETF (ASX: IXJ) I think the iShares Global Healthcare exchange traded fund (ETF) would be a fantastic option for investors looking for healthcare exposure. Through a single investment, it provides investors with access to ...

Here's why the Recce (ASX:RCE) share price has fallen 7% today
October 21st, 2020 - Motley Fool

Trading update For the period ending September 30, Recce reported a cash balance of $25.6 million due to a successful capital raise. Cash out-flows from operations came to $3.3 million with $2.5 million invested in research and development. The co...

2 defensive ASX ETFs to add to a well-balanced portfolio
October 21st, 2020 - Motley Fool

2 defensive ETFs for a well-balanced portfolio iShares Global Healthcare ETF (ASX: IXJ) Our first defensive ETF tody is this healthcare-focused fund from Blackrock’s iShares. The ASX EFT has a few high-quality health care names, like CSL Limited...

Top brokers name 3 ASX shares to buy today
October 21st, 2020 - Motley Fool

Afterpay Ltd (ASX: APT) According to a note out of Morgan Stanley, its analysts have retained their overweight rating and lifted the price target on this payments company's shares to $115. The broker notes that Afterpay has formed a partnership ...

Why CIMIC, Megaport, Mesoblast, & Temple & Webster shares are dropping lower
October 21st, 2020 - Motley Fool

CIMIC Group Ltd (ASX: CIM) The CIMIC share price is down 2% to $22.04. Investors have been selling the engineering company's shares after it advised that it will write-off a further $1 billion after losing a court battle with Chevron. This relat...

5 ASX 200 events to watch for this week
October 20th, 2020 - Motley Fool

ASX 200 events on Thursday 22 October At 7.30am on Thursday, ASX 200 company AMP Limited (ASX: AMP) will provide its Q3 update. On 2 September, AMP announced it was undertaking a portfolio review as it regularly received unsolicited offers for its...